Orbis Medicines
We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our progress: https://lnkd.in/eCH3d6ay
Orbis Medicines
We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our progress: https://lnkd.in/eCH3d6ay
TL;DR
Headquarters: Copenhagen, Denmark
Focus: Oral macrocycle drug discovery using the ^{n}Gen platform
Total disclosed funding: €116M
Founded: 2021
Employee count (approx.): 45
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Drug discovery for challenging targets using orally bioavailable macrocycles
Founded
2021
Industry
Biotechnology / Drug Discovery
Funding Track Record
€26M
Launch financing to establish the company and platform
€90M
Series A with participation from Lilly Ventures, Cormorant, EIFO, Novo Holdings, and Forbion
Investor Signal
“Venture financing led by established life-science investors (Novo Holdings, Forbion, NEA) with participation from strategic life-science investors including Lilly Ventures”